BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 2422942)

  • 1. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
    Sheibani K; Battifora H; Burke JS
    Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
    Wirth PR; Legier J; Wright GL
    Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
    Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
    J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistological study of malignant diffuse mesotheliomas of the pleura.
    Loosli H; Hurlimann J
    Histopathology; 1984 Sep; 8(5):793-803. PubMed ID: 6083969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.
    Otis CN; Carter D; Cole S; Battifora H
    Am J Surg Pathol; 1987 Jun; 11(6):445-56. PubMed ID: 2438954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry in the diagnosis of malignant mesothelioma.
    Pfaltz M; Odermatt B; Christen B; Rüttner JR
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
    Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
    Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12.
    Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE
    Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
    Oates J; Edwards C
    Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining in malignant mesotheliomas.
    Strickler JG; Herndier BG; Rouse RV
    Am J Clin Pathol; 1987 Nov; 88(5):610-4. PubMed ID: 2445194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoembryonic antigen and milk-fat globule protein staining of malignant mesothelioma and adenocarcinoma of the lung.
    Tron V; Wright JL; Churg A
    Arch Pathol Lab Med; 1987 Mar; 111(3):291-3. PubMed ID: 2435259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinction of mesothelioma from adenocarcinoma. An immunohistochemical approach.
    Battifora H; Kopinski MI
    Cancer; 1985 Apr; 55(8):1679-85. PubMed ID: 2579718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The histopathological diagnosis of malignant mesothelioma v. pulmonary adenocarcinoma: reproducibility of the histopathological diagnosis.
    Skov BG; Lauritzen AF; Hirsch F; Nielsen HW
    Histopathology; 1994 Jun; 24(6):553-7. PubMed ID: 8063283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis.
    Dejmek A; Hjerpe A
    Cytopathology; 2000 Feb; 11(1):8-17. PubMed ID: 10714371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
    Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
    Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
    Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
    Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
    Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.